Diagnosis and treatment of low-risk superficial basal cell carcinoma in a single visit

Hattier, Georgette; Duffy, Robert; Finkelstein, Mitchell; Beggs, Sarah; Lee, Jason B.

doi:10.1080/09546634.2020.1737637

Cited by 4 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective cohort study found increased BCC numbers in cSCC patients, and this and other studies point to an overlap of risk factors and pathogenesis in different skin cancer types involving immunosuppression, UVR exposure, and genetic factors [77][78][79][80][81]. The ratio of incidence BCC:cSCC of the two KC varies from a predominance of BCC in the general population to the reverse in immunosuppressed organ transplant populations; this ratio is of importance in understanding these cancers, and a call has been recently made for uniformity in the calculation of this ratio [11].…”

Section: Bcc Subtypes and Pdtmentioning

confidence: 83%

“…The most common human cancers are BCC, which comprise approximately 80% of the estimated 3.3 million keratinocyte carcinomas treated in the United States in 2012 [9][10][11]. A great deal of research in the molecular basis of BCC occurrence and development has been carried out, with the identification of important susceptibility genes [12][13][14][15][16], particularly with the unravelling of the dominant role of hedgehog signaling in the pathogenesis of BCC [16][17][18].…”

Section: Bcc As a Model Cancer For Aspects Of Pdt Researchmentioning

confidence: 99%

See 1 more Smart Citation

Photodynamic Therapy for Basal Cell Carcinoma: The Clinical Context for Future Research Priorities

Collier

Rhodes

2020

Molecules

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is an established treatment option for low-risk basal cell carcinoma (BCC). BCC is the most common human cancer and also a convenient cancer in which to study PDT treatment. This review clarifies challenges to researchers evident from the clinical use of PDT in BCC treatment. It outlines the context of PDT and how PDT treatments for BCC have been developed hitherto. The sections examine the development of systemic and subsequently topical photosensitizers, light delivery regimens, and the use of PDT in different patient populations and subtypes of BCC. The outcomes of topical PDT are discussed in comparison with alternative treatments, and topical PDT applications in combination and adjuvant therapy are considered. The intention is to summarize the clinical relevance and expose areas of research need in the BCC context, ultimately to facilitate improvements in PDT treatment.

show abstract

Section: Bcc Subtypes and Pdtmentioning

confidence: 83%

Section: Bcc As a Model Cancer For Aspects Of Pdt Researchmentioning

confidence: 99%

Photodynamic Therapy for Basal Cell Carcinoma: The Clinical Context for Future Research Priorities

Collier

Rhodes

2020

Molecules

View full text Add to dashboard Cite

show abstract

“…This outcome may have occurred by chance but is consistent with an upper bound of the 95% confidence interval of 4Á3%. 2 We do not wish to discuss the merits or otherwise of oral ivermectin in the prevention or management of COVID-19.…”

mentioning

confidence: 99%

“…Both can be treated with topical imiquimod, cryotherapy, electrodessication and curettage, excision or Mohs micrographic surgery. 2,3 Similar to the low risk of superficial BCC becoming invasive, the chance of SCCis progressing to invasive SCC is also slim, with a reported rate of 3-5%. 3,4 Although SCCis may not progress to invasive SCC frequently, high-risk locations such as the genitalia and lips, immunosuppression and depth of follicular extension often necessitate more aggressive treatment.…”

mentioning

confidence: 99%

“…Response to 'A call to standardize the BCC: SCC ratio': reply from the authors DEAR EDITOR, We thank Ma et al 1 for their interest in our article 2 and for suggesting the inclusion of squamous cell carcinoma in situ (SCCis) to the commonly used ratio, basal cell carcinoma (BCC):SCC. We agree with the authors that superficial BCC is usually managed similarly to SCCis.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Response to ‘A call to standardize the BCC:SCC ratio’

Sahni

Edwards

et al. 2021

Br J Dermatol

View full text Add to dashboard Cite

show abstract

Skin Cancer Diagnosis by Lesion, Physician, and Examination Type

Chen,

Fernandez,

Fadadu

et al. 2024

JAMA Dermatol

View full text Add to dashboard Cite

ImportanceSkin cancer is the most common cancer in the US; accurate detection can minimize morbidity and mortality.ObjectiveTo assess the accuracy of skin cancer diagnosis by lesion type, physician specialty and experience, and physical examination method.Data SourcesPubMed, Embase, and Web of Science.Study SelectionCross-sectional and case-control studies, randomized clinical trials, and nonrandomized controlled trials that used dermatologists or primary care physicians (PCPs) to examine keratinocytic and/or melanocytic skin lesions were included.Data Extraction and SynthesisSearch terms, study objectives, and protocol methods were defined before study initiation. Data extraction was performed by a reviewer, with verification by a second reviewer. A mixed-effects model was used in the data analysis. Data analyses were performed from May 2022 to December 2023.Main Outcomes and MeasuresMeta-analysis of diagnostic accuracy comprised sensitivity and specificity by physician type (primary care physician or dermatologist; experienced or inexperienced) and examination method (in-person clinical examination and/or clinical images vs dermoscopy and/or dermoscopic images).ResultsIn all, 100 studies were included in the analysis. With experienced dermatologists using clinical examination and clinical images, the sensitivity and specificity for diagnosing keratinocytic carcinomas were 79.0% and 89.1%, respectively; using dermoscopy and dermoscopic images, sensitivity and specificity were 83.7% and 87.4%, and for PCPs, 81.4% and 80.1%. Experienced dermatologists had 2.5-fold higher odds of accurate diagnosis of keratinocytic carcinomas using in-person dermoscopy and dermoscopic images compared with in-person clinical examination and images. When examining for melanoma using clinical examination and images, sensitivity and specificity were 76.9% and 89.1% for experienced dermatologists, 78.3% and 66.2% for inexperienced dermatologists, and 37.5% and 84.6% for PCPs, respectively; whereas when using dermoscopy and dermoscopic images, sensitivity and specificity were 85.7% and 81.3%, 78.0% and 69.5%, and 49.5% and 91.3%, respectively. Experienced dermatologists had 5.7-fold higher odds of accurate diagnosis of melanoma using dermoscopy compared with clinical examination. Compared with PCPs, experienced dermatologists had 13.3-fold higher odds of accurate diagnosis of melanoma using dermoscopic images.Conclusions and RelevanceThe findings of this systematic review and meta-analysis indicate that there are significant differences in diagnostic accuracy for skin cancer when comparing physician specialty and experience, and examination methods. These summary metrics of clinician diagnostic accuracy could be useful benchmarks for clinical trials, practitioner training, and the performance of emerging technologies.

show abstract

Diagnosis and treatment of low-risk superficial basal cell carcinoma in a single visit

Cited by 4 publications

References 18 publications

Photodynamic Therapy for Basal Cell Carcinoma: The Clinical Context for Future Research Priorities

Photodynamic Therapy for Basal Cell Carcinoma: The Clinical Context for Future Research Priorities

Response to ‘A call to standardize the BCC:SCC ratio’

Skin Cancer Diagnosis by Lesion, Physician, and Examination Type

Contact Info

Product

Resources

About